Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

Journal of Clinical Oncology

Volumn 32, Issue 29, 2014, Pages 3264-3274

  Ustun, Celalettin ^a   Reiter, Andreas ^c   Scott, Bart L ^j   Nakamura, Ryotaro ^k   Damaj, Gandhi ^m   Kreil, Sebastian ^c   Shanley, Ryan ^a   Hogan, William J ^b   Perales, Miguel Angel ^q   Shore, Tsiporah ^r   Baurmann, Herrad ^d   Stuart, Robert ^s   Gruhn, Bernd ^e   Doubek, Michael ^t   Hsu, Jack W ^u   Tholouli, Eleni ^v   Gromke, Tanja ^f   Godley, Lucy A ^w   Pagano, Livio ^x   Gilman, Andrew ^z   Wagner, Eva Maria ^g   Shwayder, Tor ^aa   Bornhäuser, Martin ^h   Papadopoulos, Esperanza B ^q   Böhm, Alexandra ^ab   Vercellotti, Gregory ^a   Van Lint, Maria Teresa ^y   Schmid, Christoph ⁱ   Rabitsch, Werner ^ac   Pullarkat, Vinod ^l   Legrand, Faezeh ⁿ   Yakoub Agha, Ibrahim ^o   Saber, Wael ^ad   Barrett, John ^ae   Hermine, Olivier ^p   Hagglund, Hans ^af   Sperr, Wolfgang R ^ac   Popat, Uday ^ag   Alyea, Edwin P ^ah   Devine, Steven ^ai   Deeg, H Joachim ^j   Weisdorf, Daniel ^a   Akin, Cem ^ah   Valent, Peter ^ac   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^e JENA UNIVERSITY HOSPITAL   (Germany)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁱ KLINIKUM AUGSBURG   (Germany)

^j UNIVERSITY OF WASHINGTON   (United States)

^k CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^m UNIVERSITÉ DE CAEN   (France)

ⁿ UNIVERSITY HOSPITAL OF NICE   (France)

^o LILLE UNIVERSITY HOSPITAL   (France)

^p HÔPITAL NECKER ENFANTS MALADES   (France)

^q MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^r WEILL CORNELL MEDICAL CENTER   (United States)

^s MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^t MASARYK UNIVERSITY   (Czech Republic)

^u UNIVERSITY OF FLORIDA   (United States)

^v MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^w UNIVERSITY OF CHICAGO   (United States)

^x UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^y UNIVERSITY OF GENOA   (Italy)

^z Levine Children's Hospital   (United States)

^aa HENRY FORD HOSPITAL   (United States)

^ab ELISABETHINEN HOSPITAL   (Austria)

^ac MEDICAL UNIVERSITY OF VIENNA   (Austria)

^ad MEDICAL COLLEGE OF WISCONSIN   (United States)

^ae NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^af KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^ag UNIVERSITY OF TEXAS   (United States)

^ah BRIGHAM AND WOMEN S HOSPITAL   (United States)

^ai OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GROWTH; CLINICAL EFFECTIVENESS; DONOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAST CELL LEUKEMIA; MIDDLE AGED; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SYSTEMIC MASTOCYTOSIS; UMBILICAL CORD BLOOD; ADOLESCENT; AGED; ALLOTRANSPLANTATION; CHILD; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MASTOCYTOSIS, SYSTEMIC; MULTICENTER STUDY; PROCEDURES; REMISSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84905257818     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.2018     Document Type: Article

References (77)

1. Valent P, Horny HP, Escribano L, et al: Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res 25:603-625, 2001
2. Robyn J, Metcalfe DD: Systemic mastocytosis. Adv Immunol 89:169-243, 2006
3. Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, et al: Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 124:514-521, 2009
4. Horny HP, Metcalfe DD, Bennet JM, et al: Mastocytosis, in Swerdlow SH, Campo E, Harris NL, et al (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). Lyon, France, IARC, 2008, pp 54-63
5. Ustun C, Savage NM, Gotlib J, et al: Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: A case review. Am J Hematol 87:191-193, 2012
6. Lim KH, Tefferi A, Lasho TL, et al: Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. Blood 113:5727-5736, 2009
7. Pardanani A, Lim KH, Lasho TL, et al: Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 114:3769-3772, 2009
8. Valent P, Sperr WR, Akin C: How I treat patients with advanced systemic mastocytosis. Blood 116:5812-5817, 2010
9. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al: Cladribine therapy for systemic mastocytosis. Blood 102:4270-4276, 2003
10. Kluin-Nelemans HC, Jansen JH, Breukelman H, et al: Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 326:619-623, 1992
11. Kitamura Y, Hirotab S: Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 61:2924-2931, 2004
12. Akin C: Clonality and molecular pathogenesis of mastocytosis. Acta Haematol 114:61-69, 2005
13. Nakata Y, Kimura A, Katoh O, et al: c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 91:661-663, 1995
14. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al: KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108:2366-2372, 2006
15. Nagata H, Worobec AS, Oh CK, et al: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92:10560-10564, 1995
16. Longley BJ, Tyrrell L, Lu SZ, et al: Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 12:312-314, 1996
17. Longley BJ Jr, Metcalfe DD, Tharp M, et al: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 96:1609-1614, 1999
18. Ustun C, DeRemer DL, Akin C: Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 35:1143-1152, 2011
19. Akin C, Fumo G, Yavuz AS, et al: A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103:3222-3225, 2004
20. Pardanani A, Elliott M, Reeder T, et al: Imatinib for systemic mast-cell disease. Lancet 362:535-536, 2003
21. Aichberger KJ, Sperr WR, Gleixner KV, et al: Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 38:869-873, 2008
22. Ustun C, Corless CL, Savage N, et al: Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res 33:735-741, 2009
23. Verstovsek S, Tefferi A, Cortes J, et al: Phase II study of dasatinib in Philadelphia chromosomenegative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 14:3906-3915, 2008
24. Gotlib J, Berubé C, Growney JD, et al: Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106:2865-2870, 2005
25. Gleixner KV, Mayerhofer M, Sonneck K, et al: Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 92:1451-1459, 2007
26. Gleixner KV, Mayerhofer M, Aichberger KJ, et al: PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: Comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107:752-759, 2006
27. Gupta V, Tallman MS, Weisdorf DJ: Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: Myths, controversies, and unknowns. Blood 117:2307-2318, 2011
28. Sperr WR, Drach J, Hauswirth AW, et al: Myelomastocytic leukemia: Evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res 11:6787-6792, 2005
29. Fö dinger M, Fritsch G, Winkler K, et al: Origin of human mast cells: Development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 84:2954-2959, 1994
30. Przepiorka D, Giralt S, Khouri I, et al: Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: Review of forty cases. Am J Hematol 57:24-28, 1998
31. Pullarkat VA, Bueso-Ramos C, Lai R, et al: Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: Analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 73:12-17, 2003
32. Rønnov-Jessen D, Løvgreen Nielsen P, Horn T: Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant 8:413-415, 1991
33. Pullarkat V, Bedell V, Kim Y, et al: Neoplastic mast cells in systemic mastocytosis associated with t (8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 31:261-265, 2007
34. Spyridonidis A, Thomas AK, Bertz H, et al: Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant 34:515-519, 2004
35. Nagai S, Ichikawa M, Takahashi T, et al: The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia. Exp Hematol 35:1747-1752, 2007
36. Chen TY, Chen JS, Huang WT, et al: Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 32:111-114, 2003
37. Nakamura R, Chakrabarti S, Akin C, et al: A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 37:353-358, 2006
38. Gromke T, Elmaagacli AH, Ditschkowski M, et al: Delayed graft-versus-mast-cell effect on systemic mastocytosis with associated clonal haematological nonmast cell lineage disease after allogeneic transplantation. Bone Marrow Transplant 48:732-733, 2013
39. Valentini CG, Rondoni M, Pogliani EM, et al: Mast cell leukemia: A report of ten cases. Ann Hematol 87:505-508, 2008
40. Chantorn R, Shwayder T: Death from mast cell leukemia: A young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia. Pediatr Dermatol 29:605-609, 2012
41. Valent P, Akin C, Sperr WR, et al: Aggressive systemic mastocytosis and related mast cell disorders: Current treatment options and proposed response criteria. Leuk Res 27:635-641, 2003
42. Gotlib J, Pardanani A, Akin C, et al: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 121:2393-2401, 2013
43. Oran B, Popat U, Rondon G, et al: Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. Biol Blood Marrow Transplant 19:214-220, 2013
44. Warlick ED, Cioc A, Defor T, et al: Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: Importance of pretransplant disease burden. Biol Blood Marrow Transplant 15:30-38, 2009
45. Gyurkocza B, Storb R, Storer BE, et al: Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 28:2859-2867, 2010
46. Sayer HG, Kröger M, Beyer J, et al: Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: Disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 31:1089-1095, 2003
47. Duval M, Klein JP, He W, et al: Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28:3730-3738, 2010
48. Buckley SA, Appelbaum FR, Walter RB: Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant 48:630-641, 2013
49. Ustun C, Wiseman AC, Defor TE, et al: Achieving stringent CR is essential before reducedintensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplant 48:1415-1420, 2013
50. Estey EH: Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87:89-99, 2012
51. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
52. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083, 2000
53. Wang SA, Hutchinson L, Tang G, et al: Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chromosomal abnormalities in SM and AHNMD components. Am J Hematol 88:219-224, 2013
54. Johnson RC, Savage NM, Chiang T, et al: Hidden mastocytosis in acute myeloid leukemia with t (8;21) (q22;q22). Am J Clin Pathol 140:525-535, 2013
55. Paschka P, Marcucci G, Ruppert AS, et al: Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t (8; 21): A Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-3911, 2006
56. Boissel N, Leroy H, Brethon B, et al: Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20:965-970, 2006
57. Park SH, Chi HS, Min SK, et al: Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 35:1376-1383, 2011
58. Cairoli R, Beghini A, Grillo G, et al: Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study. Blood 107:3463-3468, 2006
59. Wang YY, Zhou GB, Yin T, et al: AML1-ETO and C-KIT mutation/overexpression in t (8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A 102:1104-1109, 2005
60. Fritsche-Polanz R, Fritz M, Huber A, et al: High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol Oncol 4:335-346, 2010
61. Georgin-Lavialle S, Lhermitte L, Dubreuil P, et al: Mast cell leukemia. Blood 121:1285-1295, 2013
62. Shimoni A, Hardan I, Shem-Tov N, et al: Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity. Leukemia 20:322-328, 2006
63. Ringdén O, Labopin M, Ehninger G, et al: Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 27:4570-4577, 2009
64. Marks DI, Wang T, Pérez WS, et al: The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 116:366-374, 2010
65. McClune BL, Weisdorf DJ, Pedersen TL, et al: Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 28:1878-1887, 2010
66. Sperr WR, Mitterbauer M, Mitterbauer G, et al: Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. Clin Cancer Res 11:6536-6543, 2005
67. Sperr WR, El-Samahi A, Kundi M, et al: Elevated tryptase levels selectively cluster in myeloid neoplasms: A novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 39:914-923, 2009
68. Sperr WR, Jordan JH, Baghestanian M, et al: Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 98:2200-2209, 2001
69. Dimitriadou V, Mécheri S, Koutsilieris M, et al: Expression of functional major histocompatibility complex class II molecules on HMC-1 human mast cells. J Leukoc Biol 64:791-799, 1998
70. Banovac K, Ghandur-Mnaymneh L, Leone J, et al: Intrathyroidal mast cells express major histocompatibility complex class-II antigens. Int Arch Allergy Appl Immunol 90:43-46, 1989
71. Malaviya R, Twesten NJ, Ross EA, et al: Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells. J Immunol 156:1490-1496, 1996
72. Kambayashi T, Allenspach EJ, Chang JT, et al: Inducible MHC class II expression by mast cells supports effector and regulatory T cell activation. J Immunol 182:4686-4695, 2009
73. Warren EH, Deeg HJ: Dissecting graft-versusleukemia from graft-versus-host-disease using novel strategies. Tissue Antigens 81:183-193, 2013
74. Metcalfe DD, Peavy RD, Gilfillan AM: Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol 124:639-646, 2009
75. Lu LF, Lind EF, Gondek DC, et al: Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442:997-1002, 2006
76. Weisdorf D: GVHD the nuts and bolts. Hematology Am Soc Hematol Educ Program 62-67, 2007
77. Devine SM, Adkins DR, Khoury H, et al: Recent advances in allogeneic hematopoietic stemcell transplantation. J Lab Clin Med 141:7-32, 2003.